Alpha Teknova (NASDAQ:TKNO) Releases Quarterly Earnings Results, Meets Expectations

Alpha Teknova (NASDAQ:TKNO) issued its earnings results on Thursday. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.09), FiscalAI reports. The business had revenue of $9.98 million during the quarter, compared to analysts’ expectations of $9.62 million. Alpha Teknova had a negative net margin of 45.78% and a negative return on equity of 23.53%.

Here are the key takeaways from Alpha Teknova’s conference call:

• Solid 2025 operational and financial progress — revenue grew 7% to $45.0M, Q4 revenue was $10.0M, gross margin improved to ~33%, adjusted EBITDA loss narrowed to -$6.7M, and free cash outflow improved to -$9.8M with $21.3M in cash on hand.
• Clinical Solutions momentum — the company now serves 60 clinical customers (up from 48), supports ~70 therapies (5 in Phase 2+ and 12 in Phase 1), and expects to support at least one commercial therapy by end-2027, with commercialization potentially driving large per-therapy spend increases (~30x from early-phase levels).
• Targeted investment and path to profitability — management will add about $2M/year in commercial spend to pursue sequencing, spatial genomics, and cancer-screening customers, guides 2026 revenue to $42M–$44M, and targets adjusted EBITDA positivity by end-2027 at roughly $52M–$57M annualized revenue.
• Near-term risk and sensitivity to biotech funding and timing — management warns of a ~4-quarter lag from biotech funding to revenue, lower average revenue per customer from new additions, and potential quarter-to-quarter lumpiness from large Clinical Solutions orders, leaving 2026 upside contingent on market recovery and customer ramps.

Alpha Teknova Stock Performance

Shares of TKNO traded up $0.25 during mid-day trading on Friday, hitting $2.53. 107,152 shares of the company’s stock were exchanged, compared to its average volume of 279,198. The company has a current ratio of 5.27, a quick ratio of 4.27 and a debt-to-equity ratio of 0.18. Alpha Teknova has a fifty-two week low of $1.91 and a fifty-two week high of $7.48. The business’s 50 day moving average is $3.13 and its two-hundred day moving average is $4.26. The firm has a market capitalization of $135.48 million, a P/E ratio of -7.23 and a beta of 0.41.

Institutional Trading of Alpha Teknova

Hedge funds have recently added to or reduced their stakes in the stock. Susquehanna International Group LLP grew its stake in shares of Alpha Teknova by 25.0% in the 3rd quarter. Susquehanna International Group LLP now owns 16,206 shares of the company’s stock valued at $100,000 after purchasing an additional 3,246 shares during the last quarter. Larson Financial Group LLC lifted its holdings in shares of Alpha Teknova by 58.5% during the third quarter. Larson Financial Group LLC now owns 9,387 shares of the company’s stock worth $58,000 after purchasing an additional 3,464 shares during the period. JPMorgan Chase & Co. grew its position in Alpha Teknova by 123.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 8,163 shares of the company’s stock valued at $40,000 after buying an additional 4,504 shares during the last quarter. Bridgeway Capital Management LLC increased its stake in Alpha Teknova by 7.9% in the 3rd quarter. Bridgeway Capital Management LLC now owns 80,900 shares of the company’s stock valued at $501,000 after buying an additional 5,900 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Alpha Teknova during the 2nd quarter worth $29,000. 13.81% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Zacks Research upgraded shares of Alpha Teknova to a “hold” rating in a research note on Wednesday, December 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Alpha Teknova in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Alpha Teknova currently has a consensus rating of “Hold” and a consensus price target of $8.00.

About Alpha Teknova

Alpha Teknova, Inc (NASDAQ: TKNO) is a life science tools and reagents company that develops, manufactures and distributes proprietary products to support research, drug discovery and biomanufacturing. Its offerings target academic institutions, pharmaceutical and biotechnology firms, and diagnostic developers, with a focus on high-purity reagents and optimized workflows designed to accelerate molecular biology and protein science applications.

The company’s portfolio includes molecular biology reagents, cell culture buffers, in vitro translation kits, custom recombinant proteins, high-throughput screening buffers and other specialized formulations.